CA2546895A1 - Oxazole derivatives of tetracyclines - Google Patents

Oxazole derivatives of tetracyclines Download PDF

Info

Publication number
CA2546895A1
CA2546895A1 CA002546895A CA2546895A CA2546895A1 CA 2546895 A1 CA2546895 A1 CA 2546895A1 CA 002546895 A CA002546895 A CA 002546895A CA 2546895 A CA2546895 A CA 2546895A CA 2546895 A1 CA2546895 A1 CA 2546895A1
Authority
CA
Canada
Prior art keywords
carbon atoms
optionally substituted
dimethylamino
dioxo
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002546895A
Other languages
French (fr)
Inventor
Phaik-Eng Sum
David Brian How
Darrin William Hopper
Matthew Douglas Vera
Joshua James Sabatini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth
Phaik-Eng Sum
David Brian How
Darrin William Hopper
Matthew Douglas Vera
Joshua James Sabatini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34681543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2546895(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth, Phaik-Eng Sum, David Brian How, Darrin William Hopper, Matthew Douglas Vera, Joshua James Sabatini filed Critical Wyeth
Publication of CA2546895A1 publication Critical patent/CA2546895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Abstract

This invention provides compounds of the formula: wherein A", X and Y are defined in the specification. These compounds are useful as antibacterial agents.

Description

OXAZOLE DERIVATIVES OF TETRACYCLINES
FIELD OF THE INVENTION
The present invention relates to novel oxazole derivatives of tetracyclines which are useful as antibiotic agents and exhibit antibacterial activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines and other antibiotics. This invention also relates to novel tetracycline intermediates useful for making the novel compounds and novel methods for producing the novel compounds and the intermediate compounds.
BACKGROUND OF THE INVENTION
Since 1947 a variety of tetracycline antibiotics have been synthesized and described for the treatment of infectious diseases in man and animals. Tetracyclines inhibit protein synthesis by binding to the 30S subunit of the bacterial ribosome preventing binding of aminoacyl RNA (Chopra, Handbook of Experimental Pharmacology, Vol.
,78, 317-392, Springer-Verlag, 1985). Resistance to tetracyclines has emerged among many clinically important microorganisms which limit the utility of these antibiotics. There are two major mechanisms of bacterial resistance to tetracyclines:
a) energy-dependent efflux of the antibiotic mediated by proteins located in the cytoplasmic membrane which prevents intracellular accumulation ~of tetracycline (S.
B. Levy, et al., Antimicrob. Agents Chemotherapy 33, 1373-1374 (1989); and b) ribosomal protection mediated by a cytoplasmic protein which interacts with the ribosome such that tetracycline no longer binds or inhibits protein synthesis (A. A.
Salvers, B. S. Speers and N. B. Shoemaker, Mol. Microbiol, 4:151-156, 1990).
The efflux mechanism of resistance is encoded by resistance determinants designated tetA-tetL. They are common in many Gram-negative bacteria (resistance genes Class A-E), such as Enterobacteriaceae, Pseudomonas, Haemophilus and Aeromonas, and in Gram- positive bacteria (resistance genes Class K and L), such as Staphylococcus, Bacillus and Streptococcus. The ribosomal protection mechanism of resistance is encoded by resistance determinants designated TetM, N
and O, and is common in Staphylococcus, Streptococcus, Campylobacter, Gardnerella, Haemophilus and Mycoplasma (A. A. Salyers, B. S. Speers and N. B.
Shoemaker, Mol. Microbiol, 4:151-156 1990).
A particularly useful tetracycline compound is 7-(dimethylamino)- 6-demethyl-6-deoxytetracycline, known as minocycline (see U.S. Pat. No. 3,148,212, U.S.
Pat. No.
RE 26,253 and U.S. Pat. No. 3,226,436 discussed below). However, strains harboring the tetB (efflux in gram-negative bacteria) mechanism, but not tetK
(efflux in Staphylococcus) are resistant to minocycline. Also, strains carrying tetM
(ribosomal protection) are resistant to minocycline. This invention describes the synthesis of novel tetracycline compounds which demonstrate significant in vitro and in vivo activity vs. tetracycline and minocycline susceptible strains and some tetracycline and minocycline resistant strains, that is, those harboring the tetM
(ribosomal protection) resistance determinants.
Duggar, U.S. Pat. No. 2,482,055, discloses the preparation of Aureomycin®
by fermentation which have antibacterial activity. Growich et al., U.S. Pat. No.
3,007,965, disclose improvements to the fermentation preparation. Beereboom et al., U.S. Pat. No. 3,043,875 discloses tetracycline derivatives Boothe et al., U.S.
Pat. No, 3,148,212, reissued as U.S. Pat. No. RE 26,253, and Petisi et al., U.S. Pat.
No.
3,226,436, discloses tetracycline derivatives which are useful for treating bacterial infections. Blackwood et al., U.S. Pat. No. 3, 200,149 discloses tetracycline derivatives which possess microbiological activity. Petisi et al., U.S. Pat.
No.
3,338,963 discloses tetracycline compounds which have broad-spectrum antibacterial activity. Bitha et al., U.S. Pat. No. 3,341,585 discloses tetracycline compounds which have broad-spectrum antibacterial activity. Shu, U.S. Pat. No.
3,360,557 discloses 9- hydroxytetracyclines which have been found to possess antibacterial activity. Zambrano, U.S. Pat. No. 3,360,561 discloses a process for preparing 9-nitrotetracyclines. Martell et al., U.S. Pat. No. 3,518,306 discloses tetracyclines which possess in vivo antibacterial activity.
In U.S. Pat. No. 5,021,407 a method of overcoming the resistance of tetracycline resistant bacteria is disclosed. The method involves utilizing a blocking agent compound in conjunction with a tetracycline type antibiotic. This patent does not disclose novel tetracycline compounds which themselves have activity against resistant organisms. Described in U.S. Pat. No. 5,494,903 are 7-substituted-9-substitutedamino-6-demethyl-6-deoxytetracyclines which have broad spectrum antibacterial activity.
In summary, none of the above patents teach or suggest the novel compounds of this application. In addition, none of the above patents teach or suggest novel tetracycline compounds of the invention having activity against tetracycline and minocycline resistant strains as well as strains which are normally susceptible to tetracyclines.
SUMMARY OF THE INVENTION
In accordance with the present invention, there is provided compounds represented by Formula (I);
X ~N~
H H - OH
A / \ ~ NH2 II I OHII II
O OH O O
wherein:
X is selected from hydrogen, amino, NR"R12, alkyl of 1 to 12 carbon atoms optionally substituted , aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
A" is a moiety selected from the group:
and HN
-O
S O
R" and R'2 are each independently H or alkyl of 1 to 12 carbon atoms or R" and R'2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
R is selected from alkyl of 1 to 12 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted, -CH2NRiR2, aryl of 6, 10 or 14 carbon atoms optionally substituted, aralkyl of 7 to 16 carbon atoms optionally substituted, aroyl of 7 to 13 carbon atoms optionally substituted, SR3, heteroaryl of 5 or 6 ring atoms optionally substituted, containing 1 to 4 heteroatorns which may be the same or different, independently selected from nitrogen, oxygen and sulfur, and heteroarylcarbonyl of 5 or 6 ring atoms optionally substituted containing 1 to 4 heteroatoms which may be the same or different, independently selected from nitrogen, oxygen and sulfur;
R' and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R' and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
R3 is alkyl of 1 to 12 carbon atoms optionally substituted, -CHz-aryl optionally substituted, aralkyl of 7 to 16 carbon atoms optionally substituted, aroyl, -CH2(CO)OCH~aryl optionally substituted, -CHI-alkenyl of 2 to 12 carbon atoms optionally substituted, and -CHI-alkynyl of 2 to 12 carbon atoms optionally substituted;
with the provisos that when X is NR' R2 and R' is hydrogen, then Rz is methyl, ethyl, n-propyl, n-butyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and that when R' is methyl or ethyl then R2 is methyl, ethyl, n-propyl, 1-methylethyl, n-propyl, 1-methylpropyl, or 2-methylpropyl;
or a tautomer or pharmaceutically acceptable salts thereof.
Definitions The term alkyl as a group or part of a group means a straight or branched alkyl moiety of 1 to 12 carbon atoms which can be optionally independently substituted with 1 to 3 substituents selected from the group halogen, amino, cyano, cycloalkyl of 3 to 6 carbon atoms, alkyl of 1 to 12 carbon atoms, aryl optionally substituted, phenyl, hydroxyl, alkoxy of 1 to 12 carbon atoms, NH-alkyl of 1 to 12 carbon atoms, N-cycloalkyl of 3 to 6 carbon atoms, NH-(alkyl of i to 12 carbon atoms)-aryl optionally substituted and heterocyclyl of 3 to 8 membered ring. In some embodiments of the invention alkyl is a moiety of 1 to 6 carbon atoms. In other embodiments of the invention alkyl is a moiety of 1 to 3 carbon atoms. In other embodiments alkyl is substituted by heterocyclyl of 4 to 7 ring members (e.g. pyrrolidinyl) The term alkenyl means a straight or branched carbon chain of 2 to 12 carbon atoms having at least one site of unsaturation optionally independently substituted with 1 to 3 substituents selected from the group optionally substituted aryl, phenyl, heteroaryl, halogen, amino, cyano, alkyl of 1 to 12 carbon atoms, hydroxyl, and alkoxy of 1 to 12 carbon atoms.
The term vinyl means a moiety CH2=CH-.
As used herein the term alkoxy as a group or part of a group refers to alkyl-O-wherein alkyl is hereinbefore defined.
As used herein the term aryl as a group or part of a group, e.g., aralkyl, aroyl, means an aromatic moiety having 6, 10 or 14 carbon atoms preferably 6 to 10 carbon atoms, which can be optionally substituted with 1 to 3 substituents independently selected from halogen, nitro, cyano, alkenyl, hydroxyl, alkyl, haloalkyl, alkoxy, benzyloxy, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, methylenedioxy and phenyl. In particular, aryl is phenyl or naphthyl optionally substituted with 1 to 3 substituents. Substituted phenyl may optionally be the moiety ~>
The term aralkyl as used herein of 7 to 16 carbon atoms means an alkyl substituted with an aryl group in which the aryl and alkyl group are previously defined.
Non-limiting exemplary aralkyl groups include benzyl and phenethyl and the like.
Phenyl as used herein refers to a 6-membered carbon aromatic ring.
As used herein the term alkynyl includes both straight chain and branched moieties containing 2 to 12 carbon atoms having at least one carbon to carbon triple bond optionally substituted with 1 to 3 substituents independently selected from the group halogen, amino, cyano, alkyl of 1 to 12 carbon atoms, hydroxyl, and alkoxy of 1 to 12 carbon atoms.
As used herein the term halogen or halo means F, CI, Br or I.
As used herein the term cycloalkyl means a saturated monocyclic ring having from 3 to 6 carbon atoms. Exemplary cycloalkyl rings include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In an embodiment of the invention cycloalkyl is a moiety of 5 or 6 carbon atoms.
As used herein, R' and R2 and R" and R'2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring, where a non-limiting example is pyrrolidinyl, -N
\~

The term aroyl means an aryl-C(O)- group in which the aryl group is as previously defined. Non-limiting examples include benzoyl and naphthoyl, The term heteroaryl means an aromatic heterocyclic, monocyclic ring of 5 or 6 ring atoms containing 1 to 4 heteroatoms independently selected from O, N and S.
Heteroaryl rings may optionally be substituted with 1 to 3 substitutents selected from the group halogen, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino, alkoxy, aryloxy, -CH2OCOCH3 and carboxy. Non-limiting heteroaryl moieties optionally substituted include: furanyl, thienyl, pyridyl, tetrazolyl, imidazo, thiazolyl and the like.
Further included are benzofuranyl, benzothienyl and quinolinyl.
The term heteroarylcarbonyl means a heteroaryl-C(O)- group in which the heteroaryl group is as previously defined.
The term heterocyclyl as used herein represents a saturated 3 to 8 membered ring containing one to three heteroatoms selected from nitrogen, oxygen and sulfur.
Representative examples are pyrrolidyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, tetrahydrofuranyl and the like.
~0 The term alkylheterocyclyl means an alkyl-heterocyclyl group in which the alkyl and heterocyclyl group are previously defined. Non-limiting exemplary alkylheterocyclyl groups include moieties of the formulae:
N 'N N
and Some of the compounds of formula (I) may also exist in their tautomeric forms.
Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention. For instance, compounds of formula (I) which exist as tautomers are depicted below:
w s X \N/
OH
\ \
v/ / ~I NHZ
N'\ OI
_ R~-One embodiment of this invention is where R of Formula (I) is selected from the group alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, and alkyl-(heterocyclyl) selected from moieties of the group ~ N N Z, ~ N
an ' _~~, 'd Another embodiment of the invention is where R of Formula (I) is phenyl optionally substituted with 1 to 3 substituents. In a preferred embodiment R is selected from moieties of the group CHs F
,nnnr JVW
.nnnr H
> >
a ~ ~ , O(CH2)SCHs and C(CH3)3 A further prefierred embodiment of the invention is where R is heteroaryl. In a preferred embodiment R is selected from moieties of the group CO. I i~, ~ ~ j~.

N, and N
S
An additional embodiment of the invention is where R is alkyl of 1 to 6 carbon atoms optionally substituted, alkenyl of 2 to 6 carbon atoms optionally substituted, ~ ~NH(cycloalkyl of 5 to 6 carbon atoms), ~~NH(alkyl of 1 to 6 carbon atoms) and ~~NH(alkyl of 1 to 6 carbon atoms)-aryl optionally substituted.
In a preferred embodiment R is selected from moieties of the group H
w ' H ~ H ' r f F
C(CH3)3 H N and ' H
N \
H
An additional embodiment of the invention is where R of Formula (I) is S-alkyl of 1 to 12 carbon atoms, S-CH2-aryl optionally substituted and S-CH2(CO)OCH2aryl optionally substituted. In a preferred embodiment R is selected from moieties of the group and ~~s~
I
Preferred compounds of the invention include those selected from the group:
(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-(2,2-diphenylvinyl)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (7aS,8S,11 aS)-8-(dimethylamino)-9,11 a,13-trihydroxy-2-(2-methyl-1-propenyl)-11,12-dioxo-7,7a,8,11,11 a,12-hexahydronaphthaceno[2,1-d][1,3Joxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-tert butyl-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11 ,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxa mide, (6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-2-[(~-2-(2-fu ryl)ethenyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(~-2-phenylethenyl]-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-1 O-carboxamide, WO 2005/056538 ' PCT/US2004/040850 (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-[(~-2-(4-methoxyphenyl)ethenyl]-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-2-[(~-2-(3-methoxyphenyl)ethenyl]-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-[(E)-2-(2-methoxyphenyl)ethenyl]-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-[(E~-2-(4-fluorophenyl)ethenyl]
9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1 d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-[(E)-2-(2-fluorophenyl)ethenyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-(chloromethyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-[(dimethylamino)methyl]-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(pyrrolidin-1-ylmethyl)-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(propylamino)methyl]-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-2-[(butylamino)methyl]-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(propylamino)methyl]-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide and (6aR,7aS,8S,11 aS)-2-[(tart-butylami no)methyl]-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d]
[1,3]oxazole-10-carboxamide.
Preferred compounds of the invention include those selected from the group:
(7aS,8 S,11 aS)-8-(dimethylamino)-2-[4-(dimethylamino)phenyl]-9,11 a,13-trihydroxy-11,12-dioxo-7,7a, 8,11,11 a,12-hexahydronaphthaceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-tart butyl-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-(4-methylphenyl)-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (7aS,8S,11aS)-5,8-bis(dimethylamino)-2-(3-fluorophenyl)-9,11a,13-trihydroxy-11,12 dioxo-7,7a,8,11,11 a,12-hexahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS, 8S,11 aS)-2-(4-cyanophenyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahyd rotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-[4-(dimethylamino)phenyl]-9,11a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-(5-tert butyl-2-hydroxyphenyl)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS, 8S,11 aS)-2-[4-(benzyloxy)phenyl]-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-(2,4-dihydroxyphenyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][i ,3]oxazole-10-carboxamide, (6aR,7aS, 85,11 aS)-5,8-bis(dimethylamino)-2-(3-fluoro-4-methoxyphenyl)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-2-(1,3-benzodioxol-5-yl)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(2,4,6-trimethoxyphenyl)-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(2,4,5-triethoxyphenyl)-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-(1-methyl-1 H
i ndol-2-yl)-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-(4-tert butylphenyl)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide and (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-[4-(hexyloxy)phenyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide.
Preferred compounds include those selected from the group:
(6aR,7aS, 8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-thien-3-yl-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-( 1-benzofuran-2-yl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(di methylami no)-2-(2-furyl)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][i ,3]oxazole-10-carboxamide, f 5-[(6aR,7aS,8S,11 aS)-10-(aminocarbonyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazol-2-yl]-2-furyl}methyl acetate, (6aR,7aS,8S,11 aS)-2-(1-benzothien-3-yl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(1,3-thiazol-2-yl)-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-pyridin-4-yl-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide and (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-pyridin-3-yl-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide.
An additional embodiment of the invention is a process for the preparation of a compound of the formula w i or a pharmaceutically acceptable salt thereof wherein:
X is selected from hydrogen, amino, NR'R2, alkyl of 1 to 12 carbon atoms optionally substituted., aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
R' and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R' and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
comprising the steps:
a. reacting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula NHZ
or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula b. reacting the chloro compound with an amine R'R2NH to form a substituted amine of the formula c, hydrolyzing the substituted amine with acid to give a compound of the formula W
R~/
and d. isolating the compound or a pharmaceutically acceptable salt thereof.
In a preferred embodiment of the process X is N(CH3)2and the amine RiR2NH is t-butyl amine.
In a preferred embodiment of the process the compound [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide or a pharmaceutically acceptable salt thereof is prepared.
A further embodiment of the invention is a process for the preparation of a compound of the formula R~/

wherein:
X is selected from hydrogen, amino, NR'R2, alkyl of 1 to 12 carbon atoms optionally substituted , aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl, optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
R' and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R' and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
or a pharmaceutically acceptable salt thereof comprising the steps:
a. reacting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula b. reacting the chloro compound with acid to give 9-(2-chloromethylcarbonylamino)substituted-6-demethyl-6-deoxytetracycline of the formula c. reacting the 9-(2-chloromethylcarbonylamino)substituted-6-demethyl-6-deoxytetracycline with amine R'R2NH to give a compound of the formula w i R~/
and d. isolating the compound or a pharmaceutically acceptable salt thereof.
In a preferred embodiment of the process X is N(CH3)2and the amine R'R2NH is t-butyl amine.
In a preferred embodiment of the process the compound [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide or a pharmaceutically acceptable salt thereof is prepared.
An additional embodiment of the invention is a compound of the formula Rz/
or a pharmaceutically acceptable salt thereof wherein:
X is selected from hydrogen, amino, NRiR2, alkyl of 1 to 12 carbon atoms optionally substituted , aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
R' and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R' and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
produced by the process comprising the steps:
a. reacting 7-(substituted)-s3-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula b. reacting the chloro compound with an amine R'R2NH to form a substituted amine of the formula W
c. hydrolyzing the substituted amine with acid to give a compound of the formula and d. isolating the compound or a pharmaceutically acceptable salt thereof.
In a preferred embodiment of the process X is N(CH3)2and the amine R'R2NH is t-butyl amine.
In a preferred embodiment of the process the compound [4S-(4a,,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide or a pharmaceutically acceptable salt thereof is prepared.
In an additional embodiment of the invention a compound of the formula \/
R
~N
Rx wherein:
X is selected from hydrogen, amino, NR'R2, alkyl of 1 to 12 carbon atoms optionally substituted , aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
R' and R2 are each independently H or alkyl of 1 to 12 carbon atoms or when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyf of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
or a pharmaceutically acceptable salt thereof produced by the process comprising the steps:
a. reacting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula \/
b. reacting the chloro compound with acid to give 9-(2-chloromethylcarbonylamino)substituted-6-demethyl-6-deoxytetracycline of the formula of c. reacting the 9-(2-chloromethylcarbonylamino)substituted-6-demethyi-6-deoxytetracycline with amine R'R2NH to give a compound of the formula of ;

WO 2005/056538 ~ PCT/US2004/040850 and d. isolating the compound or a pharmaceutically acceptable salt thereof.
In a preferred embodiment of the process X is N(CH3)2and the amine R'R2NH is t-butyl amine.
In a preferred embodiment the compound [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,1 i-dioxo-2-naphthacenecarboxamide or a pharmaceutically acceptable salt thereof is prepared by the process.

DESCRIPTION OF THE PREFERRED EMBODIMENTS
The novel compounds of the present invention may be readily prepared in accordance with the following Scheme I.
The starting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracyclines 1 or pharmaceutically acceptable salts thereof where X and Y are hereinbefore defined are reacted with aldehyde RCHO in the presence of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to afford benzoxazole 2 and 3 (Procedure A). As further described, reaction of 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracyclines 1 or pharmaceutically acceptable salts thereof where X and Y are hereinbefore defined are reacted with 2-chloro-1,1,1-trimethoxy-ethane in an aprotic solvent such as N,N-dimethylformamide (DMF) to give chloromethyl-benzoxazole 4 , optionally isolated, then converted to substituted amine 5 by further reaction with an amine 9 (Procedure B) . Hydrolysis of amine 5 affords 9-(2-substituted aminomethyl carbonylamino)substituted-6-dimethyl-6-deoxytetracycline 6 (Procedure D).
Hydrolysis of chloromethylbenzoxazole 4 gives 9-(2-chloromethylcarbonyl-amino)substituted-6-demethyl-6-deoxytetracycline 7 which may be further reacted with amine 9 to give 9-(2-substituted aminomethyl carbonylamino)substituted-6-dimethyl-6-deoxytetracycline 6.
Additionally, reaction of 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracyclines 1 or pharmaceutically acceptable salts thereof with thiocarbonyldiimidazole provides thio 8 followed by alkylation with RCH2Br in the presence of an amine which includes N,N-diisopropylethylamine affords oxazole (Procedure C).
Preferably, amine 9 in the preparation of 9-(2-substituted aminomethyl carbonylamino)substituted-6-dimethyl-6-deoxytetracycline 6, in Scheme I is t-butylamine.

X ~N~
Y -H H = off Scheme I
Procedure C (Cont) I \
2) Diisopropylethylamine, RCH2Br / \Y ~I NH2 N\ ~ ~ I OHII ~ X ~N~
O O OH O O 1, H H -SCH2R O ~ OH
X ~N~ CI~ I / \Y ~I NH2 Y H H off NH ~ ~ I oHll \ OH O OH O O
I / .\Y I NH2 NH Y ~ I oHll ~ 7 ~O O OH O O
S
H+
Procedure C
1) Thiocarbonyl diimidazole OCH3 X H Fi N/ ~OCHH3 X H hi N/
Y 8 7\ OH C~ Y ~ OH
I9 / \Y ~I NHZ I / \ . I NH2 -NH2 H ~ OHOHIOI ~ ~~ ~ HOHIOI
1 CI q.
OCH3 R, Procedure A RCHO/DDO ~OCH3 N-H
\OCH3 R2 9 R~ CI ~ i X ~N~ N H Procedure B X H H N
H H - OH R 9 Y ~ OH
/ .\ I NH2 N I / \ I NHS N\ OH
R~O 02 OH HO O R~ ~O O OH O O
N~/ 5 R2 H+ Procedure D
X ~N~
Y Fi _ X ~Ni I OH Y H H -/ / _ NH2 Rt O \ OH
N\ ,N~ I / \ I NH2 ?-O OH O OHO O R2 NH -R ~ OH O OH HO O
As shown in Scheme II, the starting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracyclines 1 or pharmaceutically acceptable salts thereof where X and Y are hereinbefore defined are reacted with a methyl orthoester to afford methyl benzoxazole derivative 11. Acid hydrolysis of methyl benzoxazole derivative 11 affords N-acetyl derivative 12.
Scheme II

~OCH3 X H H N~ H3C0 OCH3 OH
/ \ I NH2 ~ NH2 NH2,' ~ ,'o~ ~ orthoester OH o off o o H+
X ~N~
OH
I / _\Y _ ~I NH2 H3C NH ~ ~ I OHII
OH o off o 0 Reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformation being effected. It is understood by those skilled in the art of organic synthesis that the various functionalities present on the molecule must be consistent with the chemical transformations proposed.
This may necessitate judgement as to the order of synthetic steps, protecting groups, if required, and deprotection conditions. Substituents on the starting materials may be incompatible with some of the reaction conditions. Such restrictions to the substituents which are compatible with the reaction conditions will be apparent to one skilled in the art.
Some of the compounds of the hereinbefore described schemes have center of asymmetry. The compounds may, therefore, exist in at least two and often more stereoisomeric forms. The present invention encompasses all stereoisomers of the compounds whether free from other stereoisomers or admixed with other stereoisomers in any proportion and thus includes, for instance, racemic mixture of enantiomers as well as the diastereomeric mixture of isomers. The absolute configuration of any compound may be determined by conventional X-ray crystal log raphy.
Pharmaceutically acceptable salts of the compounds of the invention may be obtained as metal complexes such as aluminum, calcium, iron, magnesium, manganese and complex salts; inorganic and organic salts and corresponding Mannich base adducts using methods known to those skilled in the art (Richard C.
Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, 1989).
Preferably, the compounds of the invention are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; or organic salts such as acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate alkylsulfonate or arylsulfonate. The salt formation preferentially occurs with the C(4)-dimethylamino group when forming inorganic salts. The salts are preferred for oral and parenteral administration.

Standard Pharmacological Test Procedures Methods for in Vitro Antibacterial evaluation The minimum inhibitory concentration (MIC) Antimicrobial susceptibility testing. The in vitro activities of the antibiotics are determined by the broth microdilution method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (1 ). Mueller-Hinton II
broth (MHBII)(BBL Cockeysville, MD) is the medium employed in the testing procedures.
Microtiter plates containing serial dilutions of each antimicrobial agent are inoculated with each organism to yield the appropriate density (105 CFU/ml) in a 100 ~I
final volume. The plates are incubated for 18 - 22 hours at 35°C in ambient air. The minimal inhibitory concentration for all isolates is defined as the lowest concentration of antimicrobial agent that completely inhibits the growth of the organism as detected by the unaided eye.
1. NCCLS. 2000. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards: M7-A5, vol. 20.
National Committe for Clinical Laboratory Standards, Wayne, PA.

~ O ~ ~ ~t d' d' d' d' Wit' 00 d' '~t O
O C~ N
r M

X T r z U

a~

o ~r c'r ~ o c~
c~ o ~r ~r ~r ~r ~ ~r ~r d- ~r ~ ao ~r ~
~ n ~ n ~

f- X

tJJ W

H

d' D

~ CO ~ ~ Cfl N N C~ N N N N N O N CO CO

n r n n ~- M M r M M M M M r M r r n X

H W

m M

U

~
E

C ~~C
O ONNNrNNNNNN 00 C
~ O

fti n ~

D X
LIJ

N

N

ao c~
o c~
o ao 00 00 0o ao o~ 00 0o ao 00 0o c~
o ~
~
~

~ ~ x M

lJJ m Q00 r =

~ N ~ ~ C4 N N CO CO CO N N CO CO
O O ~
M M
M

A r r r M M r r /~ /~ /~
/~ A /~ r ~U

H~

m ~

o j ~
c c c ~ ~ - - U o C O
C

~ ~ ~
C + ~ .U U - ~ () F ~ Y ~ o ~ .'~ .~ .~ ~ .~ U U
- - ~ ~
U
cn c I-> d ~
U U
~
c c ~ ~~-~~ U + ~ U U :c ~ Q
ca ~ ~ U
~ . ( U ~ _ .-. ~ U
_ ~ U
~ ~ ~ Y ~ ~ ~ ~ ~ coo ~ V
~

~ ~.
Q ~ t~
c a E U Q
> d' oo M O ao .~.
r ~ ~ Q ~r ~ ~r d' r C~ ~ CO
U ~ ~'~

.
Q ~ r co r a~ co co ~ ~ ~ ~ ~
' U

Wit ~~ ~ o ~~~M Cfl CO I~ M r Ln N N U

LLJ O O M M r ~ ~ r0 ~ N ~' N N
W

U N .~ .~ ~
~ fin U
U U U U U U ~
~ N O

U U
, Q UU _ UUUu~cnuncn~n.~.~.~ctNc C'3C~C3C'3C'3~
UUU~
U

_ ~~~~~
_ ~o~
~O _ _ ~O .O ~O ~O U ~ ~ ~ ~ ~ U U N ~ C >, (~
v= ~

Q U U U U (a (Li (IS (C3 (LS (~ ~ ~ .;~ Q
U Q Q U , u.i u.l u.! LU Cl~ c~ cl~ cl~ c~ cl~ u! ~J
1.u U~ c~ c~ cl~ ~ = U

O r N M Cf' ~.f~ CO
r N M d' LC) (O I~ 00 O r r r r r r r r r r N

r Z r d' d' 'd' d' '~' U Q- cfl co CO (O CO N d' N dwt d' d' ~ ~t N N N N
n n n n n ~ co c~ o 0 o c~ n co c~ m co c~ n n U x Q
m E

r UJ Q- O O N O O O O O O O O O O O O d' f- ~ n n C~ n n r r r r r r r O r O r ~
X
W
H
m 00 N
N CO N CO CO d' ~' d' O ~ O ~ ~ O C~ r O ('0 r r (O O CO
n n z ~-- O
I= O °' ''' cn U ~ ~ c'~no ao ctno c'~no 0o m o0 0o ao 0o co ao 00 00 ~ oo d- ~ ~
m .-. ~ . n m ~ W
m .3 pU_ u~ ~
H
H
C~ o m > .'..' j co~~.-.-. 0 0 .-. c o L ~ ~ U .,.r O C ~ ~ '''~' C _'f' ~ .U U ~ ~ U C
tW.~n ~-~ ° Y d o ° ~ .~ .~ .~ v .o U U
~ c~~a o ~~~~.~cU(~ ~ ~UU:cUQU
~ ~ ~ U y ~ ~ Y . U U ~ c ~ ~ U '-o U
c ~ U ~ w.- .,J '-'.~, W-. I-"' o ~ ~r ao ~~ r~ ~ a ~ ~ a U m U .°? ~ .°? c!~ Q Q ~ ~ ~r r cfl o°~
c°°o U ~ ~~a~rd0'd0'O~N~NN~~U~Uc~
J O O) O C~ C~? r C~ Cfl r '~' N ~' N N N U C~ * n U
Q N ~ ~ N O U U U U U U U U U c~ c~ * ~ ~ U
m N ~I' ~I' N r C'3 C'3 C'3 C'3 C~ C'3 U C'3 C'3 'o 'o ~ '~ (Cj U U U U U cn cn cn cn cn cn .~ .~ .~ c .c N c C3 C3 C'3 C'3 C'3 ~ ~ ~ ~ N ~ U U U ~ ~ ~ ca o U
~O ~O ~O ~O .O ~ ~ ~ ~ ~ ~ U N N ~ ~ ~ _ U U U U U CLf (Ci (~ (~ (CS (ii ~ ~ ~ Q Q Q U .~
- wu~Wwulc~cnUmcnc~u.m.iWC~c~U~=U
O r N C~ d' ~ CO I~ 00 O) O
Q r N C'~ ~' LC) Cfl I~ 00 ~ r r r r r r r r r r N

d' 'd' CO d' d' WO O CO CO O O ~t d' d' d' O c0 C d' d' M r ~ ~ r r T' r r r r r r Q

[.~LJ

z J
U

T

X
E- LIJ

_ p d' r m X

lJJ

.
co _ r pz C~nOd'C~ 'd'Od'OOONOOO
Od'd' O M r r r OC~

n n m U

__ r JO

o ~r oo O
n d' ~ c~ m 0o O d- 00 00 O O 00 ~r ~r pU n c~c u~

!--m U

r IL o > .,r c ~ c ~
~.-.
j o .

o -~
.
U

U - ~ V C

I- ~ .-. o ~ o U ~ .~ .~ .c v .v U U
Y

U _ ~ ~ U U ~ ~ U U :~ U Q V
~ ~ o ~ ~.
Q

_ Y ~ ~ ~ ~ ~ coo ~ V
~ H

~
Q
~ ~
~
Q
~

~ .. .r cn Q
L ~
r ~ ~
'. .~ '.

~ U U ~ c~ co N ~ ~ U U U

V O O O M C~ r CO O ~ N ~ N
C~ r d' N d' N N ~ N C~ ~ V
V

Q ~ '~ ~ ~ ~ U U U U U U U U c~ ca m U U
' ' ' N ~ '~ N C3 C'3 3 C3 C3 c ~ = ~
c C'3 C'3 C'3 U C.

UUUUUu~cn~n cncncn.~.~.~~~c~

Q c~c~c~c~~ ~ ~
~

~ _~
.
~

.~
.

U C~ (~ (Cj ~ ~ .~ Q. Q i1 U V ~ (LC
U
U
U (~ tCj (~

u.i LLi ui u.i c!~ cn c~ u.i 111 u.i cn u.i C~ (rj c~ cA c!~ ~ = U

O r N CC d' ~ CO I~ OO O
r N C~ 'd' ~ CO O
[~ 00 ~ r r r r r r r r r r N

d' d' d' d' N N N d' N d' d' N d' d- d- d-d' d' d' d' r CO CO CO CO C~ C9 C~ C~ C~ C4 C~ C~ CO CO
CO Cfl Cfl Cfl C~ CC7 N

Q

Cn W W

Z

J

U N

a~

Q Q ~ ~ N ~ ~ N N N '~t N d' d' N ~ d' N N
N

. /~ M /~ CC CC C~ O M CO CO C~
C ~ M CO M C9 /

~ / ~
~

X

H W

~
D

W O
T

X

W

.
D O

~ r ~

H ~ ~ ~ d' ~ ~ ~r ~r ~r ~t ~t ~t d- d- ~ co nU ~r co ~

.

~O

u~

J r ~O
~ a~
O

c'~ 00 ao ao ao 00 00 ~ ao ~ m ~
o ~r ~ ~ 00 ~ ~ c'~
o n ~

X

H W

f --_ H

m I~ ~

_ LL L
O
+~

>
_ C ~

O
~ O
~ =1 ~

cn .-. ~= U
~ o ~ ~ c c~ ~ -(O _ = _ ~ ~ ~ + ~ V 'V

p ~
I- . Y a o o ~ .'~ .~ .~ ~ .~ U U
U
~' .~ .~ = ~
~ '. ~ U
Q U c~a o ~- ~ U U 'c '~
c~ ~ ~
U ~ .r ... ._ U Q U

U ~U ~ U
:~ ~~Y ~
~ ~ ~c~o~V

~ ~
Q ~ t~~Q
~ >

~ ~aVmV ~~ ~UQQ~
~
r ~~~

W ~ ~ ~ ~ ~ Cfl f~ O CO CO ~ ~ N V U ~ O
U COO

I- r ~ N ~ N N
' ~ '~ Q ' ~ ~ O
T

V O O O C~ M t r ~ U
CO CO r d' N '~' N N O O (~

N ~ ~ N O ~
U ~ V U
U U U U U U U U c~ c~ ~
~

CD C3 .
N ' C'3 C'3 C'3 C'3 C'J U U U
' ~
' N r o ~t o o c~ N cn d ~n ~n ~n ~n cn .~ .~ '~ ~ ~ ~
U U U U U '~ ~ c v~

C'3C'3C'3C ~UU
'3C'3~

_ NoNa~N
1~ L Y.. 1.. 1.. 1. N N 0 1-~

U U U U U C~ (~ t~ t~ (d ~ .~ ~ Q. Q Q
(~ U .~ (Li 111 LlJ L1J (n fn fn fn cn LtJ L1J 111 c!~
L1J 111 Cn fn fn ~ = U

O r N C'9 d' Cn CC) I~ 00 O O

T N (~ d' ~ QQ ~ r r T r r r r r T r N
~ ((~

LIJ

z J O
N

N
Q ~ O C~ CO N N CO N C4 CO ~ ~
~
E
E
~
N
E
E
~

- ~
C
O C
O C
O
C
O
C
O
n ~CC n nrrrCCC9rMrr ~ n /~ I~ l~

n L!J N

N
f-~- ~ ~ n o0 ~ (~
O 00 d' 00 d~ 00 d' OO d- ~t N N c0 cfl C~
' ~
~ r r ( m d' N

d' d' d' d' D ~ O ~p N O O N N N N N ~t N N N ~t d' N ~
m m m C'~ C~ Cfl M C'~ C~ C
~

O Cfl C~ n /~ A
/~ /~
/~ /~

ti N M

N

00 C~
O ~ 00 d0 00 00 00 00 00 QO 00 N N CO CO
CC M r r O ~ ~ ~
n A

J

U

~
_ I--~

m o c .~~~.~ .-.c o c !~ U

_ _ -E ~
U U
.-.
~ ~ ~

f- .
~
_ ~ - o Y a U U ~ .can .~ .~ v .c I-~- U

o ~ ~~~~ U V ~ ~ U U :~ ~ Q V

V ~3 ~ U y c E U ~ ~ -~ ."' .,r ~r oo m U
c a ~

V m ~ .,? ~
n Q
~
~t r co ~ c o ~
Q ~ ~ ~ ~"' ~~ .- c~ ~ o~ co co '-n t~ N V V
,d ~ U co .i-~ Q - Q .~-. (~ CO Cfl f~ C~ r ~ N N U
U U U U~ O
.r U U U U U U U ~ ~ ~ i V
V
~
V

n Q C
'3 U
a~
N l (j ~ N O
C~ C~ C~ C~ C~ C~ ~
' ' .

N r N d d U N to N tn U~ tn O
U U U U U cn u~ cn ~n cn v ~

y_-_ - -m L c ~ ~ ~ ~ ~ ~ E E a~ ~, C'3 C'3 C3 C3 C3 ~ ~ ~ ~ ~ ~ U U U
O Q) U
.
.
.
.
.

z ~ C ~, (~ v= .Q
O ~ ~ ~ ~ ~ ~
O
O
O
O

Q U U U U U (~ f~ (IS (Cf (LS (ti .~ ~ ~ Q Q, Q. U .~ tLf u.i u.i ui u.i iti c~ c~ c~ vi vi cn t~ ~i u.i cn c~ vi ~ = U

O r N C'C C1' ~.f7 CO f~ 00 ~ O
r N C~ d' ~.f~ Cfl I~ 00 O) r r r r r r r r r r N

T CO Cfl ~ C4 (~ O ~Y 00 00 00 00 00 00 Op 00 00 00 Cfl d' d' c~ n n n n nn _N

Q.

W X

LIJ

J

U

a~
n c~no ao ~ c'~
o ~d- 00 00 00 00 ~r oo ~r ~t ~ c~ co ~ c'~o n u~ x E - u~

D

u~

N

N
C~nO ~ 00 (~
O n o0 00 00 00 00 00 00 00 4p N N c0 CO ~
c~0 c~ c~ r n r n n m N
D N

D ~ c'~
o c~
o ~ ~ oo ao 00 ~ ~ ao ~ 00 00 ~ ~ ~ ~ c'~
o z n n n X

W

J~ N
~

m O ~ O O ~ do ~ Do ~

n n n ~3 ~U

_ H~

m n ~

> .,r ~ ~
j o j ~~
~ ~ o .~ ~
c L
U

_I ~
U~

t-_ a o o ~ .cn .c .~ v .v U U
i.c> .-. o Y
U

U _ Q _ + ~ U U 'c .= Q '.
U ~ o ~ ~ .-. ~ U
U U ~ ;- ~ .r . U
-" U

U .~ v -~
~ U
~ ~ U y ~ ~ Y ~ U ~ ~ y.c~ ~r U '-~' ~
~

~
Q ~c EU
oc~oa oQ
~ a~
~a a~ ~~' ~>
Q

u _ l _ _ _ _ _ ~ ~ t~ cv U U ~ ~ V c~
~ ~
~ ~ U

. ~
E-- c~ ~ o~ co _ ~NN
0' ~~~a~
M
0'O~

-d N
, d n () O O O M C'9 r CO CO r ~ N d' N N ~ N (t3 ~
, N ~ ~ N O U U U U U U U U U c~ cu .x ~ ~

U
3C'3C'3UUC~~c'c ~
Nd' d'N rC'3C'3C'3( .
UUUUUcnu~v~cncncn.~.~.~ ooc~N
E ~
L
' ' ' ' ' a>

C

3~
~
UUU
~

_ ~~~~~
~~
c~a o_ .O O .O O .O ~ ~ ~ ~ ~ ~ ~
c~
~ C ~

~
, cCt C~
U U U U U (CS (~ (CS (T~ C~ (~ .~ .~. .,-Q Q Q U ._ W W W W W cn U c!~ cn U U W W 111 c!~ U U
~ = U

O r N C''~ 'd' ~ Cfl I~ 00 O O
r N ~ ~ ~ C~ ~ ~ ~ r r r r T r r r r r N

~t ~t r N ~f' ~t d' cfl 'd~ r r r r ~t ~t '~t d' N d' d-r n Q.

X

z U M

Q ' 0 0 0 0 ~.c~ ~ o 00 ~ d' ~ ~ r Op d' r ~7 r ~ N N ~ N
r ~-O O O O O O O n X
IJJ

D

W

N
Q. ~ ~ N ~ ~ N d' d- N d' N N d' N Cfl ~
N N N C
c'0 c'~ ' M O (fl M c0 Cr M

J ~ CC G~ c n n 0 r ~
n n X

W

M

M
D N

Q. ~ ~ CO d' ~ Cfl N N CO Cfl CO N M pp N
C4 (fl (O CO CEO
r ~ r r ('~ M r r r r r (~

n r n n M n H' x ~

W

W= ~ M
~U

Q~ ~ U- t~0~~~(~O~(~O~C~O~C~O~~ ~'MppCflN~C~O

E n n n n n n n n n n n o o r r M n n n c~
w ~U

_ H

m ri ~.

u. o o -, ~ o j o ~

0 o c_ c. U

I '''' C '~' ~ ,U U
.

Y a. U o ~ .v~ ~
ue- ~ o c ~ .v U
U

~ _ d ~ U U -c W Q U
U c ~ ~ .-. + ~ ~ V + -~ o ~ ~.~.~
c U

U ~ c'no ~ m I\ ~
. Q
U -~ ~ ~ Y ~ ~ ~ ~

Q Q

.~ ~. .r '. .~ ~

..-. ~ U U ~ o 0 a~Q occicoo~~c~W.~nc~o ~C'~C~d'U~o N N U
' N N ~
r ~ ~ ~

ue O d) O C'7 C9 ~ C~
' N d V V
r , d U c~ c~ * ~
N ~ ~ N O U U U U U U V
U

N d' d' N r ~ ~ ~ ~ ~ o U

~ ~ ~ ~ ~
' ~ (~ c~

C5' f.'3 U' U' ~

~o 'o -o 'o 'o ~ ~ ~ ~ ~ ~ c ~ ~ ~ ~

U U U U U (LS (LS (~ (CS .f- Q. Q. Q U ._ (LS (CS .~- .,.- (~

IJJ W W W IJJ Cf~ Cn G7 W Cn Cn CO ~ Z U
C!~ Cn (n W IJJ

rNM~~~~~~~TT~rT ~r~rr~~N

M

D o Q N N N N N N ~ d' N N N d' N d' M M M M M M M ~ C~ M M M CO M M M M
M CO

c~

I_-- W

H-M

d) ~ C'NCC'NCMCNCC7CNCC'N~~

W W

H

H

I-- M

d' N r N N d' d' 00 d' d' d' N d' N
r r r r 'CJ"

~~

m U~
~

I--~

H ~
~

_ .-. o o L
c!) > .-..-. o c .-. o ~ o ~

. c cc U
~ _c o ~ '. c c~ c~ ~ U
I
~ ~ ~
U
V ~
O

O ~ O
. U
.
t~
G' ~.
cfl o Y a o o ~ .cn .c .c v .o U
U

+ ~ U U '~ ~~ Q
f- = ~ + ~ U U
U~L.r..~.-UV
U ~ o ~.-.~.~

.~U U
~ = U U ~ Wn ~t U ~- c4 C'3 U y ~ ~ Y
, co o~ ~-~ ,~ I-~
~ o~
-.
~ I- a~ ~r oo M o0 U cn .~ ~ ~ ~r r co m U

Q ~ Q o Q ~ c~o ~ n M ~ ~ ~ ~ C'3 C.~ 't U C.
S

_ t~~cpoor'_'~~~~NUUU ~ ~~y U
V

_ N ~u7NO~C'3C'3C'3C'3C'3 ~
' ' ' o .

cn d N r N
d ~ N
o O
fO cn V U U U U U cn cn u~ tn ~n cn - -O N N O N U U U ~ O O (Lf O U

O N N O O O +' ~
~ C >, c~ ~ -_Q
O .O O O O ~ ~ ~ ~ ~ ~

~ cfi ca (CS
U U U U U (if (C5 (CS fCS Q5 O r--,- v- Q ~ Q. U .

Q u.iu.iuiuiu.iu~u~uiuiviual~iWUiu~u~u~~=ti p r N M d' ~7 CO I~ 00 O? O
r N M ~ ~ C~ ~ ~ ~ r r r T r r r r N
r r When the compounds of the invention are employed as antibacterials, they can be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.
An effective amount of compound from about 2.0 mg/kg of body weight to about 100.0 mg/kg of body weight may be administered one to five times per day via any typical route of administration including but not limited to oral, parenteral (including subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques), topical or rectal, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions of compounds of the invention from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
These active compounds may also be administered parenterally or intraperitoneally.
Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.

The invention will be more fully described in conjunction with the following specific examples which are not to be construed as limiting the scope of the invention.
Example of Procedure A

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-(2,2-diphenylvinyl)-9,11 a,12-trihydroxy 11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10 carboxamide 9-aminominocycline sulfate salt (0.500g, 0.748 mmol) is dissolved in anhydrous DMF and treated with (3-phenylcinnamaldehyde (0.779g, 3.74 mmol, 5 equivalents) The solution is then treated with DDQ (0.085 g, 0.374 mmol, 0.5 equivalents) and stirred at room temperature for 5 min. ES+ mass spectrometry showed a 1:1 ratio of product and starting material. A second portion of DDQ
(0.068 g, 0.300 mmol, 0.4 equivalents) is added. After approximately 5 minutes, acetonitrile (7.5 mL) is added, and the entire reaction mixture is poured slowly into ether (750 mL.) The pink solid is removed by filtration and washed with fresh ether to yield 0.480g of the crude product. This material is dissolved in water (75 mL) to give a solution at pH 2.2, which is extracted with dichloromethane (2 X 100 mL.) The pH of the aqueous layer is raised to 3.0 with aqueous ammonia, and the solution is again H3C~N.CH3 .. Fi3C~N~CH3 extracted with dichloromethane (2 X 100 mL.) The four organic extracts are dried (Na2S04), filtered and concentrated to a volume of about 2 mL. A small portion of methanol (1 mL) is added, and the concentrated solution is treated dropwise with 1 M
HCI in ether. The solid precipitate is filtered, washed with fresh ether and dried under vacuum the product as its HCI salt.
Selected 1 H NMR signals: 5 4.26 (s, 1 H), 7.13 (s, 1 H), 7.26-7.45 (m, 8H), 7.63 (s, 1 H), 9.08 (s, 1 H), 9.54 (s, 1 H).
The compounds of this invention listed below in Examples 2 to 37 are prepared substantially following the method described in detail hereinabove in Example using procedure A.

(7aS,8S,11aS)-8-(dimethylamino)-9,11a,13-trihydroxy-2-(2-methyl-1-propenyl)-11,12-dioxo-7,7a,8,11,11 a,12-hexahydronaphthaceno[2,1-d][i ,3]oxazole-10 carboxamide MS m/z 492 (M+H) HRMS: calcd for C2gH26N3~7, 491.16925; found (ESI+), 492.1765 H3C~N~CH3 H

(7aS, 85,11 aS)-8-(dimethylamino)-2-[4-(dimethylami no)phenyl]-9,11 a,13-trihydroxy 11,12-dioxo-7,7a, 8,11,11 a,12-hexahydronaphthaceno[2,1-d][1,3]oxazole-10 carboxamide HRMS: calcd for C3oH~9N30,, 566.1958; found (ESI+), 557.2030 (6aR,7aS,8S,11 aS)-2-tert-butyl-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d] [1,3]oxazole-10-carboxamide MS (ESI) m/z 539.3 (M+H);
MS (ESI) m/z270.4 (M+2H); , HRMS: calcd for C2gH34N4O7 ' HCI, 574.2194; found (ESI-), 537.23462;

H3C~N.CH3 H3C'N.CH3 (6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-(4-methylphenyl)-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide MS (ESI) m/z 573.3 (M+H);
MS (ESI) m/z 287 (M+2H);
HRMS: calcd for Cg1H32N4~7 ' HCI, 608.2038; found (ESI-), 571.21905;

(7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-(3-fluorophenyl)-9,11 a,13-trihydroxy-11,12 dioxo-7,7a,8,11,11 a,12-hexahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide H3C~N.CH3 .. H3C~N.CH3 H3C~N.CH3 .. H3C~N.CH3 (6aR,7aS,8S,11 aS)-2-(4-cyanophenyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy 11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10 carboxamide MS (ESI) m/z 584.4 (M+H);
HRMS: calcd for C3~H~9N50~' HCI, 619.1834; found (ESI-), 582.19817;

(6aR,7aS, 8S,11 aS)-5,8-bis(dimethylamino)-2-(4-(dimethylamino)phenyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide H3C~N.CH3 H3C~N.CH3 MS (ESI) m/z 602.2 (M+H);
MS (ESI) m/z 301.8 (M+2H);
HRMS: calcd for C32H35N5O7 ' HCI, 637.2303; found (ESI-), 600.24521;

H~C_ _CH" H"(:(;H"

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-(2,2-diphenylvinyl)-9,11 a,12-trihydroxy 11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10 carboxamide MS (ESI) m/z 661.3 (M+H);
MS (ESI) m/z331.3 (M+2H);
HRMS: calcd for C3gH36N4O7 ' HCI, 696.2351; found (ESI-), 659.24957;

(6aR,7aS,8S,11 aS)-2-(5-tert-butyl-2-hydroxyphenyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide MS (ESI) m/z 631.4 (M+H);
HRMS: calcd for C34H3aN4O8 ' HCI, 666.2456; found (ESI+), 631.27753;

H3C~N.CH3 .. H3C'N~CH3 H3C~N.CH3 H3C~N.CH3 (6aR,7aS, 8S,11 aS)-2-[4-(benzyloxy)phenyl]-5, 8-bis(dimethylamino)-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d]
[1,3]oxazole 10-carboxamide MS (ESI) m/z 665.2 (M+H);
HRMS: calcd for C37HggNqOg ' HCI, 700.2300; found (ESI+), 665.26096;

(6aR,7aS,8S,11 aS)-2-(2,4-dihydroxyphenyl)-5,8-bis(dimethylamino)-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole 10-carboxamide MS (ESI) m/z 591.2 (M+H);
HRMS: calcd for CgOH30N4Og ' HCI, 626.1780; found (ESI-), 589.1927;

H3C~N,CH3 .. H3C~N.CH3 N"r f:H" N..r ru..

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-(3-fluoro-4-methoxyphenyl)-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole 10-carboxamide MS (ESI) m/z 607.3 (M+H);
MS (ESI) m/z 304 (M+2H);
HRMS: calcd for C31H31FN4Og' HCI, 642.1893; found (ESI-), 605.20519;

(6aR,7aS,8S,11 aS)-2-(1,3-benzodioxol-5-yl)-5,8-bis(dimethylamino)-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole 10-carboxamide MS (ESI) m/z 603.3 (M+H);
MS (ESI) m/z302.1 (M+2H);
HRMS: calcd for C31H30N4~9 ' HCI, 638.1780; found (ESI+), 603.20953;

H3C~N.CH3 .. H3C'N.CH3 H3G~N.CH3 .. H3C~N~CH3 (6aR,7aS, 8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(2,4,6 trimethoxyphenyl)-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-carboxamide MS (ESI) m/z 649.2 (M+H);
HRMS: calcd for C3gH36N4~10 ' HCI, 684.2198; found (ESI-), 647.23441;

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(2,4,5 triethoxyphenyl)-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-carboxamide H, MS (ESI) m/z 691.3 (M+H);
HRMS: calcd for C36Ha2Na0,o ' HCI, 726.2668; found (ESI+), 691.29817;

HsC~N.CH3 .. H3C~N.CH3 H3C~N.CH3 .. H3C~N.CH3 (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-thien-3-yl-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide MS (ESI) m/z 565.2 (M+H);
MS (ESI) m/z283.4 (M+2H);
HRMS: calcd for C2gH2gN40~S ' HCI, 600.1445; found (ESI-), 563.15992;

(6aR,7aS,8S,11 aS)-2-(1-benzofuran-2-yl)-5,8-bis(dimethyiamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide MS (ESI) m/z599.3 (M+H);
HRMS: calcd for C32H3oN4O8 ' HCI, 634.1830; found (ESI-), 597.19811;

H3C~N~CH3 .. H3C~N~CH3 H~C_ _CH~ H"C rH"

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-( 1-methyl-1 H
indol-2-yl)-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][i ,3]oxazole 10-carboxamide H3C~N,CH3 H3C~N.CH3 H H =
OH

O N ~ I ~ I NH2 OH~
~O O OH O O
O

MS (ESI) m/z 612.2 (M+H);
HRMS: calcd for CggH33N5~7' HCI, 647.2147; found (ESI+), 612.24406;

(6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-2-(2-furyl)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide MS (ESI) m/z 549.3 (M+H);
HRMS: calcd for C28H~8N40$ ' HCI, 584.1674; found (ESI-), 547.1822;

H3C~N.CH3 H3C~N,CH3 {5-[(6aR,7aS,8 S,11 aS)-10-(aminocarbonyl)-5,8-bis(dimethylamino)-9,11 a,12 trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazol-2 yl]-2-furyl}methyl acetate MS (ESI) m/z 621.2 (M+H);
HRMS: calcd for Cg1 H32N4~10 ' HCI, 656.1885; found (ESI+), 621.21807;

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-[(E)-2-(2-furyl)ethenyl]-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][i ,3]oxazole 10-carboxamide MS (ESI) m/z 575.2 (M+H);
MS (ESI) m/z 288.3 (M+2H);
HRMS: calcd for C3pH30N4~8 ' HCI, 610.1830; found (ESI-), 573.1985;

H3C~N,CH3 .. H3C~N.CH3 H3C~N.CH3 .. H3C~N.CH3 (6aR,7aS,8S,11 aS)-2-(1-benzothien-3-yl)-5, 8-bis(dimethylamino)-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d]
[1,3]oxazole 10-carboxamide MS (ESI+) m/z 615.1 ((M+H)+);
HRMS: calcd for C32H30N4~7S ' HCI, 650.1602; found (ESI+), 615.19036;

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(1,3 thiazol-2-yl)-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10 carboxamide HsC. .CHs HsC~ .CHs _0H
' ~ ~ ' NH2 N
O
MS (ESI) m/z566.4 (M+H);
MS (ESI) m/z283.6 (M+2H);
HRMS: calcd for C2~H2~N5O7S ' HCI, 601.1398; found (ESI+), 566.16973;
H3C~N,CH3 .. H3C'N~CH3 (6aR,7aS, 85,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(E~-2 phenylethenyl]-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-carboxamide Hz MS (ESI) m/z585.4 (M+H);
MS (ESI) m/z 293.3 (M+2H);
HRMS: calcd for C32H32N407' HCI, 620.2038; found (ESI+), 585.2329;

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-[(E)-2-(4-methoxyphenyl)ethenyl]-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide MS (ESI) m/z 615.3 (M+H);
MS (ESI) m/z 308.3 (M+2H);
HRMS: calcd for C3gH34N4~8 ' HCI, 650.2143; found (ESI+), 615.24413;

H3C~N~CH3 .. H3C~N~CH3 H.~C_ _CH~ H~C_ _CH~

(6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-[(~-2-(3 methoxyphenyl)ethenyl]-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1 d][1,3]oxazole-10-carboxamide H3C~N~CH3 .. H3C'N~CH3 MS (ESI) m/z 615.4 (M+H);
MS (ESI) m/z308.3 (M+2H);
HRMS: calcd for CggH34N408 ' HCI, 650.2143; found (ESI+), 615.24419;

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-[(~-2-(2-methoxyphenyl)ethenyl]-11,13-dioxo-6, 6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide ~~ ~a MS (ESI) m/z 615.3 (M+H);
MS (ESI) m/z308.3 (M+2H);
HRMS: calcd for Ce3gH34N4~8 ' HCI, 650.2143; found (ESI+), 615.24408;

H3C~N,CH3 .. ti3C~N~CH3 (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-[(E)-2-(4-fluorophenyl)ethenyl]
9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1 d][1,3]oxazole-10-carboxamide H3C~N~CH3 .. H3C~N~CH3 MS (ESI) m/z 603.3 (M+H);
MS (ESI) m/z 302.3 (M+2H);
HRMS: calcd for Cg2H31FN4O7' HCI, 638.1944; found (ESI+), 603.22476;

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-[(E~-2-(2-fluorophenyl)ethenyl]
9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1 d][1,3]oxazole-10-carboxamide MS (ESI) m/z 603.2 (M+H);
MS (ESI) m/z 302.3 (M+2H);
HRMS: calcd for C32H31 FN4O7 ' HCI, 638.1944; found (ESI+), 603.22469;

H3C~N~CH3 .. H3C~N~CH3 (6aR,7aS,8S,11 aS)-2-(4-tert butylphenyl)-5,8-bis(dimethylamino)-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole 10-carboxamide MS (ESI) m/z 615.3 (M+H);
MS (ESI) m/z 308.3 (M+2H);
HRMS: calcd for C34H3gN4O7 ' HCI, 650.2507; found (ESI+), 615.28057;

H3C~N.CH3 .. H3C~N.CH3 (6aR,7aS, 85,11 aS)-5,8-bis(dimethylamino)-2-[4-(hexyloxy)phenyl]-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d]
[1,3]oxazole 10-carboxamide H3C~N.CH3 H3C~N.CH3 H H OH
/ ~ ( NH2 N~ O O Of-I°HO O
O

MS (ESI) m/z 659.4 (M+H);
MS (ESI) m/z 330.4 (M+2H);
HRMS: calcd for C3gH42N4~g ' HCI, 694.2769; found (ESI+), 659.30693;

(6aR,7aS, 8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2 pyridin-4-yl-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d] [1,3]oxazole-10 carboxamide H3C, .CH3 H3C, .CH3 N"'' MS (ESI-) mlz 558.4 ((M-H)-);

(6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-pyridin-3-yl-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide MS (ESI) m/z560.3 (M+H);
MS (ESI) m/z280.7 (M+2H);
HRMS: calcd for C2gH2gN5O7' HCI, 595.1834; found (ESI+), 560.21353;

(6aR,7aS,8S,11 aS)-2-(chloromethyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahyd rotetraceno[2,1-d][1,3]oxazole-10-carboxamide MS (ESI) m/z531.2 (M+H);
MS (ESI) m/z266.3 (M+2H);

H3C~N.CH3 .. H3C'N.CH3 H3C~N.CH3 .. H3C~N.CH3 (6aR,7aS,8 S,11 aS)-5,8-bis(dimethylamino)-2-[(dimethylami no)methyl]-9,11 a,12 trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole 10-carboxamide \ _ . NH2 N ~"
~N-CH3 MS (ESI) m/z540.4 (M+H);
MS (ESI) m/z270.7 (M+2H);
HRMS: calcd for C27H33N5O7 ' HCI, 575.2147; found (ESI+), 540.24506;

(6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(pyrrolidin-1-ylmethyl)-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide ~'VH2 MS (ESI) m/z566.4 (M+H);
MS (ESI) m/z283.9 (M+2H);
HRMS: calcd for C2gH35N5O7 ' HCI, 601.2303; found (ESI+), 566.26066;

H3C~N.CH3 H3C~N.CH3 H H =
H3C~N.CH3 .. H3C~N.CH3 Example of Procedure B

(6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(propylamino)methyl]-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide H3C~N,CH3 H3C~N.CH3 H H=
= OH
HsC / _~ I NH2 ~O O OHOHO O
--~N
H
9-aminominocycline sulfate salt (1.0 g, 1.50 mmol) is dissolved in DMF (50 mL) and treated with a solution of 2-chloro-1,1,1-trimethoxyethane (0.463 g, 3.00 mmol, 2 equivalents). The reaction is stirred at room temperature until mass spectrometry shows conversion to the chloromethylbenzoxazole derivative. The solution is then treated with n-propylamine (10 mL, excess) and stirred until mass spectrometry shows conversion to the n-propylaminomethyl benzoxazole. The mixture is concentrated under reduced pressure to remove excess n-propylamine, and then poured slowly into ether (1 L) and HCI/ether is added to precipate the salt.
The solid is rinsed with fresh ether and dried under vacuum. The crude solid is dissolved in water (100 mL) giving a solution at pH 2. The pH is raised successively by 0.5 units with aqueous ammonia, and extracted with dichloromethane. The fractions extracted at pH 4-4.5 are combined, dried (Na~S04), filtered and concentrated nearly to dryness. A small volume of methanol is added and the solution is treated with HCI in ether. The precipitated solid is collected by filtration, washed with fresh ether and dried under vacuum to yield 0.067 g of the product as its HCI salt.
Selected 1 H NMR signals: 8 0.94 (t, 3H), 1.73 (m, 2H), 4.31 (s, 1 H), 4.65 (s, 2H), 7.78 (s, 1 H), 9.15 (s, 1 H), 9.67 (s, 1 H).

The compounds of this invention listed below in Examples 39 to 41 are prepared substantially following the method described in detail hereinabove in Example using procedure B.
(prepared from Procedure B) (6aR,7aS,8S,11 aS)-2-[(butylamino)methyl]-5,8-bis(dimethylamino)-9,11 a,12 trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,'11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole 10-carboxamide H3C~N,CH3 H3C~N.CH3 H H =
CH3 ~ OH
_\ I NH2 N -H
~O O OHO O O
~'N
H
1~ MS (ESI) rn/z568.3 (M+H);
MS (ESI) m/z284.8 (M+2H);
MS (ESI) m/z 305.2 (M+ACN+2H);
HRMS: calcd for C29H3~N50, ' HCI, 603.2460; found (ESI+), 568.27616;
~.0 (Procedure B) (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(propylamino)methyl]-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d]
[1,3]oxazole-10-carboxamide H3C~N.CH3 H3C~N.CH3 H OH
H3C ( / ~ I NH2 N -~O O OHOHO O
N
H
MS (ESI) m/z 554.3 (M+H);
MS (ESI) m/z277.7 (M+2H);
HRMS: calcd for C2gH35N5O~ ' HCI, 589.2803; found (ESI+), 554.2604;
(Procedure B) (6aR,7aS,8S,11 aS)-2-[(tert-butylamino)methyl]-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide H3C~ .CH3 H3C~ .CH3 H3C~CH3 9-aminominocycline sulfate salt (1.0 g, 1.50 mmol) is dissolved DMF (20 mL) and treated with a solution of 2-chlorotrimethoxyethane (0.35 g, 2.2 mmol, 1.46 equivalents). The reaction is stirred at room temperature until mass spectrometry showed conversion to the chloromethylbenzoxazole derivative. The solution is then treated with t butylamine (7.3 mL, excess) and stirred until mass spectrometry showed conversion to the t butylaminomethyl benzoxazole. The mixture is concentrated under reduced pressure to remove excess t butylamine, and then poured slowly into ether (1 L) and HCI/ether is added to precipate the salt.
The solid is rinsed with fresh ether and dried under vacuum. The crude solid is dissolved in water (100 mL) giving a solution at pH 2. The pH is raised successively by 0.5 units with aqueous ammonia, and extracted with dichloromethane. The fractions extracted at pH 4-4.5 are combined, dried (Na2S04), filtered and concentrated nearly to dryness. A small volume of methanol is added and the solution is treated with HCI in ether. The precipitated solid is collected by filtration, washed with fresh ether and dried under vacuum to give the product as its HCI salt.
MS (ESI+) m/z568.4 ((M+H)+);
MS (ESI+) m/z284.9 ((M+2H)2+);
MS (ESI+) m/z 146.3 ((M'+H)+);
HRMS: calcd for C~gH37N5O7 ' HCI, 603.2460; fou nd (ESI-), 566.26087;
Example of Procedure C

(6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-thioxo-2,3,6,6a,7,7a,8,11,11a,13-decahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide H3C~N~CH3 H3C~N~CH3 ~H~H~ ,OH
HN ~ ~ ~ NH2 ~O O OHOHO O

To a solution of 9-amino-mino disulfate (0.668 g, 1 mmol) in DMSO (30 mL) is added 2 equivalents of 1,1-thiocarbonyldiimidazole. The reaction is then stirred at room temperature for 2 to 12 hr (followed by MS(ES)). The mixture then triturated with diethyl ether and the solid collected. Material is used in the next step without further purification.
MS (ESI) m/z 515.2 (M+H);
HRMS: calcd for C24H26N4O7S ~ H2SO4, 612.1196; found (ESI+), 515.15934;
The compounds of this invention listed below in Examples 43 to 44 are prepared substantially following the method described in detail hereinabove in Example using procedure C.
Example of procedure C
(Procedure C) benzyl {[(6aR,7aS,8S,11aS)-10-(aminocarbonyl)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahyd rotetraceno[2,1-d][1,3]oxazol-2-yl]thio}acetate H3C~N~CH3 H3C~N~CH3 To a solution of (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-2-thioxo-2,3,6,6a,7,7a,8,11,11 a,13-decahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide (Example 42) in N,N-dimethylformamide (DMF) is added 2 equivalents of diisopropylethylamine, after stirring for 5 min. 1.2 equivalent of benzyl-2-bromoacetate is added. The reaction mixture is stirred for 1 for and mixture triturated with diethyl ether and solid is collected. It is purified by extraction.
MS (ESI) m/z 663.2 (M+H);
MS (ESI) m/z332.1 (M+2H);
HRMS: calcd for CggH34N4~9S ' HCI, 698.1813; found (ESI+), 663.2115;

(6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-[(4-fluorobenzyl)thio]-9,11 a,12 trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d] [
1,3]oxazole 10-carboxamide The compound of the example is prepared using procedure D in Example 43 using fluorobenzylbromide.
MS (ESI) m/z 622.9 (M+H);
HRMS: calcd for C31H31FN40,S ' HCI, 658.1664; found (ESI+), 623.19689;

H3C~N~CH3 H3C~N~CH3 Example of Procedure D (Compound 1 to 4 to 6) Example 45 [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,~0,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
(mono HCI); (free base) 9-aminominocycline sulfate salt (1.0 g, 1.50 mmol) is dissolved DMF (20, mL) and treated with a solution of 2-chlorotrimethoxyethane (0.35 g, 2.2 mmol, 1.47 equivalents). The reaction is stirred at room temperature until mass spectrometry showed conversion to the chloromethylbenzoxazole derivative. The solution is then treated with t butylamine (7.3 mL, excess) and stirred until mass spectrometry showed conversion to the t butylaminomethyl benzoxazole. The mixture is concentrated under reduced pressure to remove excess t butylamine, and then poured slowly into ether (1 L) and HCUether is added to precipate the salt.
The solid is rinsed with fresh ether and dried under vacuum. The crude solid is dissolved in water (100 mL) giving a solution at pH 2. The pH is raised successively by 0.5 units with aqueous ammonia, and extracted with dichloromethane. The fractions extracted at pH 4-4.5 are combined, dried (Na2S04), filtered and concentrated nearly to dryness. A small volume of methanol is added and the solution is treated with HCI in ether. The precipitated solid is collected by filtration, washed with fresh ether and dried under vacuum to give the product as its HCI salt.

Product from example 41 is treated with aqueous acid for one hour to 24 hour to give mono HCL salt of example 45 MS (ESI+) m/z 586.4 ((M+H)+;
The following examples are prepared using similar method described in procedure D.
Example 46 [4S-(4cc,4aa,5aa,12aoc)]-4,7-Bis(dimethylamino)-9-[(dimethyamino)acetylamino]
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2 naphthacenecarboxamide.
MS (FAB) m/z 558 ((M+H)+;
Example 47 [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-9-[[(n-butylamino)acetyl]amino]-1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
~NH
~N
II H
O
MS (FAB) m/z586 ((M+H)+;

Example 48 [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-9-[[(propylamino)acetyl]amino]
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2 naphthacenecarboxamide MS (FAB) m/z 572 ((M+H)+;
Example 49 [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-9-[(chloroacetyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide of MS (FAB) m/z 549 ((M+H)+;

Claims (40)

  1. WHAT IS CLAIMED IS:

    A compound of Formula (I);

    wherein:

    X is selected from hydrogen, amino, NR11R12, alkyl of 1 to 12 carbon atoms optionally substituted , aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;

    A" is a moiety selected from the group:

    R11 and R12 are each independently H or alkyl of 1 to 12 carbon atoms or R11 and R12 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;

    Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;

    R is selected from alkyl of 1 to 12 carbon atoms optionally substituted, alkenyl of 2 to 6 carbon atoms optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted, -CH2NR1R2, aryl of 6, 10 or 14 carbon atoms optionally substituted, aralkyl of 7 to 16 carbon atoms optionally substituted, aroyl of 7 to 13 carbon atoms optionally substituted, SR3, heteroaryl of 5 or 6 ring atoms optionally substituted, containing 1 to 4 heteroatoms which may be the same or different, independently selected from nitrogen, oxygen and sulfur, and heteroarylcarbonyl of 5 or 6 ring atoms optionally substituted containing 1 to 4 heteroatoms which may be the same or different, independently selected from nitrogen, oxygen and sulfur;

    R1 and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R1 and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;

    R3 is alkyl of 1 to 12 carbon atoms optionally substituted, -CH2-aryl optionally substituted, aralkyl of 7 to 16 carbon atoms optionally substituted, aroyl, -CH2(CO)OCH2aryl optionally substituted, -CH2-alkenyl of 2 to 12 carbon atoms optionally substituted, and -CH2-alkynyl of 2 to 12 carbon atoms optionally substituted;

    with the proviso that when X is NR1R2 and R1 is hydrogen, then R2 is methyl, ethyl, n-propyl, n-butyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
    and that when R1 is methyl or ethyl then R2 is methyl, ethyl, n-propyl, 1-methylethyl, n-propyl, 1-methylpropyl, or 2-methylpropyl;

    or a tautomer or a pharmaceutically acceptable salt thereof.
  2. 2. A compound according to claim 1 wherein R is phenyl optionally substituted with 1 to 3 substituents or a pharmaceutically acceptable salt thereof.
  3. 3. A compound according to claim 1 wherein R of Formula (I) is selected from the group alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, and alkyl-heterocyclyl or a pharmaceutically acceptable salt thereof.
  4. 4. A compound according to claim 3 wherein alkyl-heterocyclyl is selected from moieties of the group or a pharmaceutically acceptable salt thereof.
  5. 5. A compound according to claim 2 wherein R is selected from moieties of the group or a pharmaceutically acceptable salt thereof.
  6. 6. A compound according to claim 1 wherein R is heteroaryl or a pharmaceutically acceptable salt thereof.
  7. 7. A compound according to claim 6 wherein R is selected from moieties selected from the group or a pharmaceutically acceptable saltthereof.
  8. 8. A compound according to claim 1 wherein R is alkyl of 1 to 6 carbon atoms optionally substituted, alkenyl of 2 to 6 carbon atoms optionally substituted, or a pharmaceutically acceptable salt thereof.
  9. 9. A compound according to claim 1 wherein R is selected from moieties or a pharmaceutically acceptable salt thereof.]
  10. 10. A compound according to claim 1 wherein R is S-alkyl of 1 to 12 carbon atoms, S-CH2-aryl optionally substituted and S-CH2(CO)OCH2aryl optionally substituted or a pharmaceutically acceptable salt thereof.
  11. 11. A compound according to claim 10 wherein R is selected from moieties of the group or a pharmaceutically acceptable salt thereof.
  12. 12. A compound according to any one of claims 1 to 11 wherein Y is H.
  13. 13. A compound according to any one of claims 1 to 12 wherein X is -NMe2.
  14. 14. A compound according to claim 1 selected from the group:

    (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-(2,2-diphenylvinyl)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (7aS,8 S,11aS)-8-(dimethylamino)-9,11 a,13-trihydroxy-2-(2-methyl-1-propenyl)-11,12-dioxo-7,7a,8,11,11a,12-hexahydronaphthaceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-2-tert butyl-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d] [1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-[(E)-2-(2-furyl)ethenyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(E)-2-phenylethenyl]-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-[(E)-2-(4-methoxyphenyl)ethenyl]-11,13-dioxo-6, 6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-[(E)-2-(3-methoxyphenyl)ethenyl]-11,13-dioxo-6, 6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-[(E)-2-(2-methoxyphenyl)ethenyl]-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno(2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-[(E)-2-(4-fluorophenyl)ethenyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-[E)-2-(2-fluorophenyl)ethenyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d](1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-2-(chloromethyl)-5, 8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-[(dimethylamino)methyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-(pyrrolidin-1-ylmethyl)-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(propylamino)methyl]-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-2-[(butylamino)methyl]-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-2-[(propylamino) methyl]-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide and (6aR,7aS,8S,11aS)-2-[(tert butylamino)methyl]-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide; or a pharmaceutically acceptable salt thereof.
  15. 15. A compound according to claim 1 selected from the group:

    (7aS,8S,11 aS)-8-(dimethylamino)-2-[4-(dimethylamino)phenyl]-9,11 a,13-trihydroxy-11,12-dioxo-7,7a,8,11,11 a,12-hexahydronaphthaceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-tert-butyl-5,8-bis(dimethylamino)-9,11 a,12-tri hydroxy-11,13-dioxo-6,6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-2-(4-methylphenyl)-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (7aS,8S,11 aS)-5, 8-bis(dimethylamino)-2-(3-fluorophenyl)-9,11 a,13-trihydroxy-11,12-dioxo-7,7a,8,11,11 a,12-hexahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-(4-cyanophenyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5, 8-bis(dimethylamino)-2-[4-(dimethylamino)phenyl]-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d]
    [1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-2-(5-tert butyl-2-hydroxyphenyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-[4-(benzyloxy)phenyl]-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-(2,4-dihydroxyphenyl)-5,8-bis(dimethylamino)-9,11 a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11 a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-5,8-bis(dimethylamino)-2-(3-fluoro-4-methoxyphenyl)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11 aS)-2-(1,3-benzodioxol-5-yl)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-2-(2,4,6-trimethoxyphenyl)-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d](1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-2-(2,4,5-triethoxyphenyl)-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-2-(1-methyl-1H
    indol-2-yl)-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-2-(4-tert-butylphenyl)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide and (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-[4-(hexyloxy)phenyl]-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide or a pharmaceutically acceptable salt thereof.
  16. 16. A compound according to claim 1 selected from the group:
    (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-2-thien-3-yl-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS, 8S,11aS)-2-(1-benzofuran-2-yl)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-(2-furyl)-9,11a,12-trihydroxy-11,13-dioxo-6, 6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, {5-[(6aR,7aS,8S,11aS)-10-(aminocarbonyl)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazol-2-yl]-2-furyl}methyl acetate, (6aR,7aS,8S,11aS)-2-(1-benzothien-3-yl)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5, 8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-2-(1,3-thiazol-2-yl)-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide, (6aR,7aS,8S,11aS)-5, 8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-2-pyridin-4-yl-6, 6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide and (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-9,11a,12-trihydroxy-11,13-dioxo-2-pyridin-3-yl-6,6a,7,7a, 8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide or a pharmaceutically acceptable salt thereof.
  17. 17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
  18. 18. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal a pharmacologically effective amount of a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.
  19. 19. A process for the preparation of a compound of the formula or a pharmaceutically acceptable salt thereof wherein:
    X is selected from hydrogen, amino, NR11R12, alkyl of 1 to 12 carbon atoms optionally substituted , aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl, optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
    R1 and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R1 and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
    R11 and R12 are each independently H or alkyl of 1 to 12 carbon atoms or R11 and R12 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;

    Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
    comprising the steps:
    a. reacting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula b. reacting the chloro compound with an amine R1R2NH to form a substituted amine of the formula c. hydrolyzing the substituted amine with acid to give a compound of the formula d. isolating the compound or a pharmaceutically acceptable salt thereof.
  20. 20. The process according to claim 19 wherein X is N(CH3)2.
  21. 21. The process according to claim 19 or claim 20 wherein the amine R1R2NH is t-butyl amine.
  22. 22. The process according to any one of claims 19 to 21 wherein the aprotic solvent is N,N-dimethylformamide.
  23. 23. The process according to any one of claims 19 to 22 wherein [4S-(4.alpha.,4a.alpha.,5a.alpha.,12a.alpha.)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide or a pharmaceutically acceptable salt thereof is prepared.
  24. 24. A process for the preparation of a compound of the formula wherein:
    X is selected from hydrogen, amino, NR11R12, alkyl of 1 to 12 carbon atoms optionally substituted , aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl, optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
    R1 and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R1 and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
    R11 and R12 are each independently H or alkyl of 1 to 12 carbon atoms or R11 and R12 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
    Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl, alkenyl of 2 to 12 carbon atoms optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
    or a pharmaceutically acceptable salt thereof comprising the steps:
    a. reacting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula b. reacting the chloro compound with acid to give 9-(2-chloromethylcarbonylamino)substituted-6-demethyl-6-deoxytetracycline of the formula c. reacting the 9-(2-chloromethylcarbonylamino)substituted-6-demethyl-6-deoxytetracycline with amine R'R2NH to give a compound of the formula e. isolating the compound or a pharmaceutically acceptable salt thereof.
  25. 25. The process according to claim 24 wherein X is N(CH3)2.
  26. 26. The process according to claim 24 or claim 25 wherein the amine R1R2NH is t-butyl amine.
  27. 27. The process according to any one of claims 24 to 26 wherein the aprotic solvent is N,N-dimethylformamide.
  28. 28. The process according to any one of claim 24 to 27 wherein [4S-(4.alpha.,4a.alpha.,5a.alpha.,12a.alpha.)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide or a pharmaceutically acceptable salt thereof is prepared.
  29. 29. A compound of the formula or a pharmaceutically acceptable salt thereof wherein:
    X is selected from hydrogen, amino, NR11R12, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl, optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
    R1 and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R1 and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;
    R11 and R12 are each independently H or alkyl of 1 to 12 carbon atoms or R11 and R12 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;

    Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;
    produced by the process comprising the steps:
    a. reacting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula b. reacting the chloro compound with an amine R1R2NH to form a substituted amine of the formula c. hydrolyzing the substituted amine with acid to give a compound of the formula d. isolating the compound or a pharmaceutically acceptable salt thereof.
  30. 30. The product produced by the process according to claim 29 wherein X is N(CH3)2.
  31. 31. The product produced by the process according to claim 29 or claim 30 wherein the amine R1R2NH is t-butyl amine.
  32. 32. The product produced by the process according to any one of claims 29to 31 wherein the aprotic solvent is N,N-dimethylformamide.
  33. 33. The product produced by the process according to any one of claims 29 to which is [4S-(4.alpha.,4a.alpha.,5a.alpha.,12a.alpha.)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide or a pharmaceutically acceptable salt thereof.
  34. 34. A compound of the formula wherein:

    X is selected from hydrogen, amino, NR11R12, alkyl of 1 to 12 carbon atoms optionally substituted , aryl of 6, 10 or 14 carbon atoms optionally substituted, vinyl optionally substituted, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;

    R1 and R2 are each independently H or alkyl of 1 to 12 carbon atoms or R1 and R2 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;

    R11 and R12 are each independently H or alkyl of 1 to 12 carbon atoms or R11 and R12 when optionally taken together with the nitrogen atom to which each is attached form a 3 to 7 membered saturated hydrocarbon ring;

    Y is selected from hydrogen, alkyl of 1 to 12 carbon atoms optionally substituted, aryl of 6, 10 or 14 carbon atoms optionally substituted, alkenyl of 2 to 12 carbon atoms optionally substituted, vinyl, alkynyl of 2 to 12 carbon atoms optionally substituted and halogen;

    or a pharmaceutically acceptable salt thereof produced by the process comprising the steps:

    a. reacting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula b. reacting the chloro compound with acid to give 9-(2-chloromethylcarbonylamino)substituted-6-demethyl-6-deoxytetracycline of the formula c. reacting the 9-(2-chloromethylcarbonylamino)substituted-6-demethyl-6-deoxytetracycline with amine R1R2NH to give a compound of the formula d. isolating the compound or a pharmaceutically acceptable salt thereof.
  35. 35. The product prepared by the process according to claim 34 wherein X is N(CH3)2.
  36. 36. The product prepared by the process according to claim 34 or claim 35 wherein the amine R1R2NH is t-butyl amine.
  37. 37. The product prepared by the process according to any one of claims 32 to wherein the aprotic solvent is N,N-dimethylformamide.
  38. 38. The product prepared by the process according to any one of claims 34 to which is [4S-(4a,4a.alpha.,5a.alpha.,12a.alpha.)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethylamino)acetylamino]-1,4,4a,5,5a, 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide or a pharmaceutically acceptable salt thereof.
  39. 39. A process for preparing a compound of formula I according to claim 1 which comprises a). reacting 7-(substituted)-8-(substituted)-9-amino-6-demethyl-6-deoxytetracycline of the formula or a pharmaceutically acceptable salt thereof with 2-chlorotrimethoxyethane in an aprotic solvent to afford a chloro compound of the formula wherein the variables are as defined in claim 1;

    or b. reacting a chloro compound of formula wherein the variables are as defined in claim 1; with an amine R1R2NH to form a substituted amine of the formula or c) converting a basic compound of formula I as defined in claim 1 to a pharmaceutically acceptable salt thereof or vice versa.
  40. 40. A process for preparing a compound of formula:

    wherein the variables are as defined in claim 34 which comprises:

    a) reacting a 9-(2-chloromethylcarbonylamino)substituted-6-demethyl-6-deoxytetracycline of the formula with an amine R~R2NH to give a compound of the formula or b) hydrolyzing a substituted amine of formula wherein the variables are as defined in claim 29, with acid to give a compound of the formula and if desired converting the product to a pharmaceutically acceptable salt thereof.
CA002546895A 2003-12-08 2004-12-07 Oxazole derivatives of tetracyclines Abandoned CA2546895A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52792803P 2003-12-08 2003-12-08
US60/527,928 2003-12-08
US58482304P 2004-07-01 2004-07-01
US60/584,823 2004-07-01
PCT/US2004/040850 WO2005056538A1 (en) 2003-12-08 2004-12-07 Oxazole derivatives of tetracyclines

Publications (1)

Publication Number Publication Date
CA2546895A1 true CA2546895A1 (en) 2005-06-23

Family

ID=34681543

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002546895A Abandoned CA2546895A1 (en) 2003-12-08 2004-12-07 Oxazole derivatives of tetracyclines

Country Status (25)

Country Link
US (3) US7176225B2 (en)
EP (2) EP2157085B1 (en)
JP (1) JP4848287B2 (en)
KR (1) KR101164262B1 (en)
CN (1) CN100545151C (en)
AR (1) AR047274A1 (en)
AT (2) ATE444290T1 (en)
AU (1) AU2004297243B2 (en)
BR (1) BRPI0417421A (en)
CA (1) CA2546895A1 (en)
CO (1) CO5700818A2 (en)
CR (1) CR8437A (en)
DE (1) DE602004023417D1 (en)
EC (1) ECSP066605A (en)
ES (2) ES2372635T3 (en)
IL (2) IL176162A (en)
MY (1) MY146098A (en)
NO (1) NO20062629L (en)
PA (1) PA8619601A1 (en)
PE (1) PE20050995A1 (en)
RU (1) RU2415844C2 (en)
SG (1) SG148216A1 (en)
TW (1) TW200528437A (en)
UA (2) UA83266C2 (en)
WO (1) WO2005056538A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767912C (en) * 2004-05-21 2015-08-11 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
AU2005299294B2 (en) 2004-10-25 2012-06-07 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
AR057033A1 (en) * 2005-05-27 2007-11-14 Wyeth Corp TIGECICLINE AND METHODS TO PREPARE 9-NITROMINOCICLINE
AR057324A1 (en) * 2005-05-27 2007-11-28 Wyeth Corp TIGECICLINE AND METHODS TO PREPARE 9-AMINOMINOCICLINE
AR057032A1 (en) * 2005-05-27 2007-11-14 Wyeth Corp TIGECICLINE AND PREPARATION METHODS
JP2009502809A (en) * 2005-07-21 2009-01-29 パラテック ファーマシューティカルズ インコーポレイテッド 10-Substituted Tetracycline and Method of Use
JP5335664B2 (en) 2006-04-07 2013-11-06 プレジデント アンド フェロウズ オブ ハーバード カレッジ Synthesis of tetracycline and its analogs.
WO2008127361A2 (en) 2006-10-11 2008-10-23 President And Fellows Of Harvard College Synthesis of enone intermediate
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
US8121767B2 (en) * 2007-11-02 2012-02-21 GM Global Technology Operations LLC Predicted and immediate output torque control architecture for a hybrid powertrain system
WO2009062963A1 (en) * 2007-11-14 2009-05-22 Sandoz Ag Crystalline forms of tigecycline hydrochloride
CA2730377C (en) 2008-07-11 2017-09-19 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
ES2528490T3 (en) 2008-12-18 2015-02-10 Sandoz Ag Crystalline form C of tigecycline dihydrochloride and methods for its preparation
US9073829B2 (en) 2009-04-30 2015-07-07 President And Fellows Of Harvard College Synthesis of tetracyclines and intermediates thereto

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26253A (en) * 1859-11-29 Vegetable-cutter
US2482055A (en) 1948-02-11 1949-09-13 American Cyanamid Co Aureomycin and preparation of same
US3007965A (en) 1959-02-13 1961-11-07 American Cyanamid Co New tetracyclines produced by streptomyces aureofaciens
US3043875A (en) 1959-10-22 1962-07-10 Pfizer & Co C Halogenated tetracycline derivatives and processes for their preparation
FR1430859A (en) 1960-05-23 1966-05-25
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
US3148212A (en) 1961-12-22 1964-09-08 American Cyanamid Co Reductive alkylation process
US3360557A (en) 1963-05-10 1967-12-26 American Cyanamid Co 9-hydroxytetracyclines and a process of preparing same
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
US3341585A (en) 1966-05-06 1967-09-12 American Cyanamid Co Substituted 7-and/or 9-amino-6-deoxytetracyclines
US3360561A (en) 1967-06-19 1967-12-26 American Cyanamid Co Nitration of tetracyclines
US3518306A (en) 1968-02-19 1970-06-30 American Cyanamid Co 7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines
US4806529A (en) 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US5494903A (en) * 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
DE69232302D1 (en) * 1991-10-04 2002-01-31 American Cyanamid Co 7-Substituted-9-substituted amino-6-demethyl-6-deoxy-tetracyclines
US5328902A (en) * 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
CA2378990A1 (en) * 1999-08-10 2001-02-15 Siegfried B. Christensen, Iv 1,4-substituted 4,4-diaryl cyclohexanes
EP2329828A1 (en) * 2001-07-13 2011-06-08 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of ischaemia

Also Published As

Publication number Publication date
ATE444290T1 (en) 2009-10-15
EP1692117A1 (en) 2006-08-23
JP2007515411A (en) 2007-06-14
US7176225B2 (en) 2007-02-13
EP1692117B1 (en) 2009-09-30
PE20050995A1 (en) 2006-01-11
KR101164262B1 (en) 2012-07-09
JP4848287B2 (en) 2011-12-28
AU2004297243B2 (en) 2011-02-17
SG148216A1 (en) 2008-12-31
EP2157085A1 (en) 2010-02-24
TW200528437A (en) 2005-09-01
RU2006118367A (en) 2008-01-20
UA83266C2 (en) 2008-06-25
CN1890226A (en) 2007-01-03
CR8437A (en) 2006-10-06
US20080064667A1 (en) 2008-03-13
PA8619601A1 (en) 2006-03-24
CO5700818A2 (en) 2006-11-30
IL176162A (en) 2011-09-27
IL206050A0 (en) 2010-11-30
BRPI0417421A (en) 2007-03-13
NO20062629L (en) 2006-09-06
WO2005056538A1 (en) 2005-06-23
ATE525365T1 (en) 2011-10-15
EP2157085B1 (en) 2011-09-21
KR20060105047A (en) 2006-10-09
AR047274A1 (en) 2006-01-11
MY146098A (en) 2012-06-29
UA83268C2 (en) 2008-06-25
CN100545151C (en) 2009-09-30
US20080177080A1 (en) 2008-07-24
US20050153944A1 (en) 2005-07-14
AU2004297243A1 (en) 2005-06-23
DE602004023417D1 (en) 2009-11-12
ES2372635T3 (en) 2012-01-25
ECSP066605A (en) 2006-10-25
ES2331574T3 (en) 2010-01-08
IL206050A (en) 2013-01-31
US7365087B2 (en) 2008-04-29
RU2415844C2 (en) 2011-04-10
IL176162A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
US7365087B2 (en) Oxazole derivatives of tetracyclines
EP0535346B1 (en) 9-amino-7-substituted-6-demethyl-6-deoxytetracyclines
EP1240133B1 (en) Methods of preparing substituted tetracyclines with transition metal-based chemistries
US7812008B2 (en) 9-substituted tetracyclines
JP4686189B2 (en) Methods of using substituted tetracycline compounds to modulate RNA
US20130029943A1 (en) Methods of Preparing Substituted Tetracyclines with Transition Metal-Based Chemistries
HU219973B (en) Process for producing 7-(substituted)-9-(substituted- amino)-6-demethyl-6-deoxytetracycline derivatives and pharmaceutical compositions comprising such compounds
MXPA06006542A (en) Oxazole derivatives of tetracyclines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131209